VA
HELP

VR Adviser’s Helus Pharma Inc. Common Stock HELP Stock Holding History

VR Adviser’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.5M Hold
3,851,654
– – 0.77% 21
2026
Q1 		$18.5M Buy
3,851,654
+11,404
+0.3% +$73.8K 0.69% 27
2025
Q4 		$31.4M Buy
+3,840,250
New +$24.7M 1.55% 19

Other funds holding HELP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

VR Adviser's HELP Position: Q2 2026 in Review

VR Adviser held its Helus Pharma Inc. Common Stock (HELP) position steady in Q2 2026 at 3,851,654 shares worth $25.5M. The position accounts for 0.77% of the portfolio, ranked #21.

VR Adviser first reported a position in HELP in Q4 2025 and has held it in 3 quarters since. The position peaked at $31.4M in Q4 2025. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • VR Adviser held 3,851,654 shares of Helus Pharma Inc. Common Stock worth $25.5M as of Q2 2026.
  • VR Adviser left its Helus Pharma Inc. Common Stock share count unchanged in Q2 2026.
  • Helus Pharma Inc. Common Stock made up 0.77% of VR Adviser's portfolio in Q2 2026, its #21 holding.
  • VR Adviser first reported a position in Helus Pharma Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • VR Adviser's Helus Pharma Inc. Common Stock position peaked at $31.4M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.